CDMOs face challenges that go far beyond optimizing a single step for yield and purity.

CDMOs face challenges that go far beyond optimizing a single step for yield and purity.

This week we had the opportunity to visit one of our first clients, Pharmaron, to see how they tackle these challenges on the ground.

A huge thank you to Filip Horvat-Gerber for taking the time to guide us through both the labs and the pilot plant. 

Walking through these facilities was a reminder of the complexity and ambition required to deliver reliable processes that ultimately impact patients’ lives.

We reflected on past collaborations around building robust predictive models that help scientists make better, faster experimental decisions. 

And we looked ahead to new capabilities we’re developing at ReactWise such as in-depth chemical featurization, enabling much deeper molecular insights into categorical parameters and their role in process performance.

For us, it’s incredibly valuable to exchange ideas with partners who are at the forefront of applied R&D. 

We’re extremely grateful for Pharmaron’s trust and openness in working with us from such an early stage, and excited about where we can go together.

Partnerships like this are what make it possible to move beyond incremental improvements and towards a more data-driven, predictive, and scalable future for chemical R&D.

‍